Immune Response Dynamics in Solid Organ Transplant Recipients

The immune response in recipients of solid organ transplants is shaped by a delicate interplay between host defence mechanisms and therapeutic immunosuppression intended to prevent graft rejection. Innate immune cells, including dendritic cells and natural killer cells, provide the first line of defence yet are modulated by calcineurin inhibitors, antiproliferative agents and corticosteroids. Adaptive immunity, encompassing T lymphocytes and B lymphocytes, must generate sufficient alloimmune tolerance to the graft while retaining the capacity to respond to pathogens and vaccines. T-cell subsets undergo phenotypic shifts characterised by changes in activation markers, memory formation and exhaustion profiles under the influence of immunosuppressive regimens. B cells in transplant recipients display altered differentiation kinetics, with reduced plasmablast formation and impaired germinal centre reactions leading to attenuated antibody titres. Donor-specific antibodies and subclinical rejection episodes further complicate the landscape, requiring careful monitoring of humoral and cellular biomarkers. Recent advances in high-dimensional flow cytometry and single-cell transcriptomics have begun to map these dynamics in finer detail, enabling personalised adjustment of immunosuppression, optimised vaccination schedules and improved prediction of infection risk. This integrated understanding is vital for enhancing long-term graft survival and patient health on a global scale.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Immune Response Dynamics in Solid Organ Transplant Recipients publication trend

The graph below shows the total number of articles in immune response dynamics in solid organ transplant recipients across all publications each year (not limited to Nature Index journals).

Technical terms

Alloimmune response: Host immune reaction against non-self antigens on a transplanted organ, principally mediated by T and B lymphocytes.

Calcineurin inhibitor: A class of immunosuppressive drugs (e.g. tacrolimus, ciclosporin) that block T-cell activation by inhibiting the phosphatase calcineurin.

Plasmablast: Short-lived, antibody-secreting B cell that arises early in the humoral immune response before formation of long-lived plasma cells.

Donor-specific antibody: Antibody produced by the recipient’s immune system that recognises antigens expressed by the donor organ and can mediate graft injury.

Immunological exhaustion: A state of T-cell dysfunction characterised by reduced proliferative capacity, effector function and sustained expression of inhibitory receptors.

References

1. Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY. The Lancet Rheumatology (2023).
2. Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipients. EBioMedicine (2023).
3. Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England. BMC Medicine (2024).